When Justin and Josh met in the Brown University dorms, they had no idea that they would one day be providing potential hope to patients with ALS around the world. With a shared passion for biomedicine and neuroscience, they began brainstorming solutions for neurodegenerative diseases. One of their first ideas was to treat two neuro pathways simultaneously, and they quickly received promising results. But how can two young innovators enter the complex world of pharmaceutical development and clinical trials? They formed a company, Amylyx Pharmaceuticals, Inc., and found their way to Thermo Fisher Scientific. Together, Thermo Fisher and Amylyx worked seamlessly to solve development and manufacturing challenges. Eight years later, the innovative solution Justin and Josh dreamed up from their dorms, is now in clinical trials and shows promising evidence of slowing disease progression and extending life for patients with ALS.